Get started
Author

Yanelda García-Vega

Observed names: Garcia-Vega Y, García Vega, Yanelda, Y Garcia-Vega, Yanelda Garcia Vega, Yanelda Garcia-Vega, Yanelda Garcìa Vega, Yanelda García Vega
ORCID: 0000-0001-5534-6090
Observed ORCID: 0000-0001-5534-6090
OpenAlex ID: A5008440586
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials
2022 · María Eugenia-Toledo-Romaní, Leslyhana Verdecia-Sánchez, et al. · Vaccine · 39
PDF
Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study
2009 · Lorenzo Anasagasti-Angulo, Yanelda Garcia-Vega, et al. · BMC Cancer · 35
PDF
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults
2022 · María Eugenia Toledo-Romani, Mayra García-Carmenate, et al. · Med · 29
PDF
HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment
2018 · Iraldo Bello-Rivero, Yanelda Garcia-Vega, et al. · Seminars in Oncology · 29
Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers
2016 · for the CIGB-128-A Study Group, Idrian García-García, et al. · BMC Pharmacology and Toxicology · 21
PDF
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children
2022 · Rinaldo Puga-Gómez, Yariset Ricardo-Delgado, et al. · International Journal of Infectious Diseases · 20
Bioequivalence of two recombinant granulocyte colony-stimulating factor formulations in healthy male volunteers
2005 · Francisco Hernández-Bernal, Idrian García-García, et al. · Biopharmaceutics & Drug Disposition · 17
Development of a new formulation of interferons (HEBERPAG) for BCC treatment
2013 · Bello-Rivero I, Garcia-Vega Y, et al. · Journal of Cancer Research & Therapy · 15
PDF
Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG®) in patients with mycosis fungoides: an open-label trial
2012 · Yanelda García-Vega, Idrian García-García, et al. · BMC Pharmacology and Toxicology · 13
PDF
Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial
2022 · María Eugenia Toledo-Romani, Mayra García-Carmenate, et al. · medRxiv · 5
PDF
HeberFERON, formulation based on IFNs alpha2b and gamma for the treatment of non-melanoma skin cancer
2017 · Lorenzo Anasagasti Angulo, Yanelda Garcia Vega, et al. · Australasian Medical Journal · 5
Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children
2022 · Rinaldo Puga-Gómez, Yariset Ricardo-Delgado, et al. · medRxiv · 4
PDF
Basal cell carcinoma treated with HeberFERON. A real world retrospective study
2021 · C Martínez-Suárez, Y Roben-Aguilar, et al. · medRxiv · 2
PDF
First-in-human evaluation of a no-alpha interleukin–2 mutein: safety and preliminary pharmacodynamic and clinical effect
2025 · Iraida Caballero Aguirrechu, Braulio Mestre Fernández, et al. · Frontiers in Immunology · 1
PDF
Five years follow-up of patients with non-melanoma skin cancer treated with HeberFERON
2022 · Y Duncan-Roberts, Y Garcia-Vega, et al. · medRxiv · 1
PDF
Immunoglobulin E-Dependent Regulation of the CCR3 Chemokine Receptor by Interferon-Gamma in Atopic Asthmatics
2008 · Yanelda García-Vega, Judith Rodríguez-Perez, et al. · International Archives of Allergy and Immunology · 1
Seguridad, inmunogenicidad y eficacia de las vacunas SOBERANA ® 02 y SOBERANA® Plus en población pediátrica
2025 · Puga-Gómez, Rinaldo, Fonseca Hernández, Mercedes, et al. · Anales de la Academia de Ciencias de Cuba
Five years follow-up of patients with non-melanoma skin cancer treated with HeberFERON.
2024 · Yaquelin Duncan Roberts, Yanelda García Vega, et al. · Research Square
Five years follow-up of patients with non-melanoma skin cancer treated with HeberFERON
2024 · Yaquelin Duncan Roberts, Yanelda García Vega, et al. · Research Square
Safety and Immunogenicity of Anti-SARS-CoV-2 Conjugate Vaccine SOBERANA 02: Phase IIb Clinical Trial
2022 · Maria Eugenia-Toledo-Romani, Mayra García Carmenate, et al. · SSRN Electronic Journal
Seguridad del HeberFERON( en pacientes con carcinoma basal palpebral
2021 · Irene Rojas Rondón, Lázaro Vigoa Aranguren, et al. · DOAJ (DOAJ: Directory of Open Access Journals)
Respuesta clínica del tratamiento con HerberFERON( en pacientes con carcinoma basal palpebral
2021 · Irene Rojas Rondón, Lázaro Vigoa Aranguren, et al. · DOAJ (DOAJ: Directory of Open Access Journals)
Efecto Y Seguridad Del Acm Anti Cd20 (cimabior®) En Pacientes Con Lnh Indolente Refractario O Recaída
2017 · Yanelda García-Vega · Revista cubana de hematología, inmunología y hemoterapia
Seguridad Clínica Del Anticuerpo Monoclonal Cimabior® En Pacientes Con Linfoma No Hodgkiniano: Revisión Integrada De Datos
2017 · Yanelda García-Vega · Revista cubana de hematología, inmunología y hemoterapia
Seguridad Y Efecto Clínico Del Anticuerpo Monoclonal Cimabior® (anti Cd20) En Pacientes Cubanos Con Linfoma No Hodgkinianos
2017 · Yanelda García-Vega · Revista cubana de hematología, inmunología y hemoterapia
Works count: 27
Citation count: 237
H-index: 9
I10-index: 9
Year
Topic
Type